0000899243-22-002870.txt : 20220121
0000899243-22-002870.hdr.sgml : 20220121
20220121160602
ACCESSION NUMBER: 0000899243-22-002870
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220119
FILED AS OF DATE: 20220121
DATE AS OF CHANGE: 20220121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brudnick Richard
CENTRAL INDEX KEY: 0001692359
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39615
FILM NUMBER: 22545989
MAIL ADDRESS:
STREET 1: BIOVERATIV INC.
STREET 2: 225 SECOND AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Codiak BioSciences, Inc.
CENTRAL INDEX KEY: 0001659352
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: 617-949-4100
MAIL ADDRESS:
STREET 1: 35 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
FORMER COMPANY:
FORMER CONFORMED NAME: Codiak Biosciences, Inc.
DATE OF NAME CHANGE: 20151125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-19
0
0001659352
Codiak BioSciences, Inc.
CDAK
0001692359
Brudnick Richard
C/O CODIAK BIOSCIENCES, INC.
35 CAMBRIDGEPARK DRIVE, SUITE 500
CAMBRIDGE
MA
02140
0
1
0
0
See Remarks
Stock Option (Right to Buy)
7.21
2022-01-19
4
A
0
41000
0.00
A
2032-01-18
Common Stock
41000
41000
D
Restricted Stock Units
2022-01-19
4
A
0
8400
0.00
A
Common Stock
8400
8400
D
25% of this option shall vest and become exercisable on January 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
Each restricted stock unit represents a contingent right to receive one share of common stock.
On January 19, 2022, the reporting person was granted 8,400 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
Officer title: Chief Business Officer and Head of Corporate Strategy
/s/ Yalonda Howze, Attorney-in-Fact for Richard Brudnick
2022-01-21